01 January 2005
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH
Silvia Peñuelas, Véronique Noé, Raúl Morales, Carlos J. CiudadMed Sci Monit 2005; 11(1): BR6-12 :: ID: 13864
Abstract
Background: Methotrexate (MTX) is an inhibitor of dihydrofolate reductase (DHFR), an enzyme involved in nucleotide synthesis, and is widely used in therapy, but its effi cacy is often compromised by the development of resistance in cancer cells. To identify potential targets as modulators in MTX chemotherapy, we determined gene expression profi les upon MTX treatment. Material/Methods: Expression profi les in human erythroleukemia K562 cells were determined after short treatment with MTX or once resistance to MTX was established. Screening was performed using the Atlas Human Cancer 1.2K arrays (BD-Clontech[sup]®[/sup]) containing 1176 cancer-related cDNAs. Specifi c software (Atlas Image 2.0.1 and Gene Spring 6.1) was used to analyze the expression level for each gene in each condition. Results were validated by quantitative RT-PCR, and the cytotoxicity of the
different treatments was assessed by the MTT assay. Results: Differentially expressed genes were selected considering a factor of 2 with respect to their expression in control cells. Eight genes were found to be overexpressed and 14 underexpressed both in MTX-treated and resistant cells. Among the overexpressed genes we chose 5’-onophosphate dehydrogenase (IMPDH2) for further validation. Changes in IMPDH2 mRNA levels were confi rmed and functional analyses were performed by inhibiting IMPDH with either benzamide riboside, mycophenolic acid, or tiazofurin. These inhibitors sensitized resistant K562 cells to MTX cytotoxicity. Conclusions: Expression of IMPDH2 is increased in K562 cells upon short treatment with MTX and once resistance to MTX is established. Benzamide riboside, mycophenolic acid, and tiazofurin could act as modulators of MTX chemotherapy in K562 cells.
Keywords: Antimetabolites, Antineoplastic - pharmacology, Cell Survival - drug effects, Gene Expression Profiling, IMP Dehydrogenase - antagonists & inhibitors, IMP Dehydrogenase - metabolism, K562 Cells, Leukemia, Erythroblastic, Acute, Methotrexate - pharmacology, Oligonucleotide Array Sequence Analysis, Transcription, Genetic, Antimetabolites, Antineoplastic - pharmacology, Cell Survival - drug effects, Gene Expression Profiling, IMP Dehydrogenase - metabolism, K562 Cells, Leukemia, Erythroblastic, Acute, Methotrexate - pharmacology, Oligonucleotide Array Sequence Analysis, Transcription, Genetic
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952